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ABSTRACT: Charcot–Marie–Tooth disease type 2D
(CMT2D) is an autosomal-dominant axonal peripheral
neuropathy characterized by impaired motor and sensory
function in the distal extremities. Mutations in the glycyl-
tRNA synthetase (GARS) gene cause CMT2D. GARS
is a member of the ubiquitously expressed aminoacyl-
tRNA synthetase (ARS) family and is responsible for
charging tRNA with glycine. To date, 13 GARS muta-
tions have been identified in patients with CMT disease.
While functional studies have revealed loss-of-function
characteristics, only four GARS mutations have been rig-
orously studied. Here, we report the functional evaluation
of nine CMT-associated GARSmutations in tRNA charg-
ing, yeast complementation, and subcellular localization
assays. Our results demonstrate that impaired function is
a common characteristic of CMT-associated GARS mu-
tations. Additionally, one mutation previously associated
with CMT disease (p.Ser581Leu) does not demonstrate
impaired function, was identified in the general popula-
tion, and failed to segregate with disease in two newly
identified families with CMT disease. Thus, we propose
that this variant is not a disease-causing mutation. To-
gether, our data indicate that impaired function is a key
component of GARS-mediated CMT disease and empha-
size the need for careful genetic and functional evaluation
before implicating a variant in disease onset.
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Introduction
Charcot–Marie–Tooth (CMT) disease encompasses a clinically
and genetically heterogeneous group of distal, symmetric polyneu-
ropathies characterized by muscle weakness and loss of sensation
in the extremities [Reilly et al., 2011; Millecamps and Julien, 2013].
CMT disease is the most common inherited peripheral neuropa-
thy and is estimated to affect one in 2,500 individuals worldwide
[Skre, 1974]. To date, over 80 loci have been associated with CMT
disease [Timmerman et al., 2014], which is divided into two major
subclasses based on electrophysiological studies. Patients with de-
myelinating CMTdisease (CMT1) have decreasedmotor nerve con-
duction velocities (MNCVs) due to defects in myelinating Schwann
cells [Dyck and Lambert, 1968]. Not surprisingly, genes implicated
in CMT1 have important roles in myelination including peripheral
myelin protein 22 (PMP22) [Patel et al., 1992] and myelin protein
zero (MPZ) [Hayasaka et al., 1993]. Patients with axonal CMT dis-
ease (CMT2) have normal MNCVs but decreased amplitudes of
evoked muscle action potentials due to axonal dysfunction [Dyck
and Lambert, 1968]. Also consistent with electrophysiological stud-
ies, certain genes associated with CMT2 encode proteins critical for
axon function including mitofusin 2 (MFN2) [Zu¨chner et al., 2004]
and neurofilament light chain (NEFL) [Mersiyanova et al., 2000].
Interestingly, mutations in six genes encoding enzymes indispens-
able for protein translation have been implicated in CMT disease
with an axonal pathology [Antonellis et al., 2003; Jordanova et al.,
2006; Latour et al., 2010; McLaughlin et al., 2010; Vester et al., 2012;
Gonzalez et al., 2013].
Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed,
essential enzymes responsible for charging tRNA molecules with
cognate amino acids—the first step of protein translation—in the
cytoplasm and mitochondria [Delarue, 1995]. There are 37 ARS
genes in the human nuclear genome that code for 17 cytoplasmic,
17 mitochondrial, and three bifunctional enzymes; the latter group
charge tRNA in both cellular compartments [Antonellis and Green,
2008]. Glycyl-tRNA synthetase (GARS; MIM #600287) mutations
have been identified in patients with CMT2D or distal spinal mus-
cular atrophy type V (dSMA-V), two autosomal-dominant forms
of axonal peripheral neuropathy characterized by distal muscle at-
rophy, which is typically more severe in the hands [Christodoulou
et al., 1995; Ionasescu et al., 1996; Pericak-Vance et al., 1997; Sam-
buughin et al., 1998; Ellsworth et al., 1999; Antonellis et al., 2003].
Subsequently, mutations in the tyrosyl- (YARS; MIM #603623),
alanyl- (AARS; MIM #601065), histidyl- (HARS; MIM #142810),
C© 2014 WILEY PERIODICALS, INC.
andmethionyl- (MARS;MIM#156560) tRNA synthetase genes have
been implicated in dominantly inherited CMT disease with an ax-
onal pathology [Jordanova et al., 2006; Latour et al., 2010; Vester
et al., 2012; Gonzalez et al., 2013]. Finally, one individual with CMT
disease plus multiple neurological and non-neurological sequelae
was found to be compound heterozygous for twomutations in lysyl-
tRNA synthetase (KARS; MIM #601421) [McLaughlin et al., 2010].
The occurrence of mutations in multiple ARS family members sug-
gests a commonpathogenicmechanismofARS-related axonal CMT
disease.
While there is strong genetic evidence linking ARS mutations
to CMT disease, the molecular pathology underlying the axonal
phenotype remains unknown. A number of hypotheses have been
presented regarding themechanismofARS-associatedCMTdisease,
including both loss- and gain-of-function effects [Antonellis and
Green, 2008;Motley et al., 2010;Wallen andAntonellis, 2013]. Since
ARSs are responsible for charging tRNAmoleculeswith aminoacids,
one possibility is that ARS-associated CMT disease is caused by the
failure to charge sufficient quantities of tRNA; mutations in ARS
genesmay inhibit tRNAcharging by impairing enzyme activity or by
altering proper cellular localization [Antonellis and Green, 2008].
As a result, the translational machinery may not be able to meet
the demand for protein synthesis in highly metabolic, terminally
differentiated motor and sensory axons.
To date, functional studies performed on a subset of CMT-
associated ARS mutations have revealed loss-of-function charac-
teristics. All nine of the YARS, KARS, AARS, HARS, and MARS
mutations tested to date cause a severe decrease in enzyme activity
and/or an inability to rescue deletion of the endogenousARS gene in
yeast complementation assays [Jordanova et al., 2006; McLaughlin
et al., 2010, 2011; Vester et al., 2012; Gonzalez et al., 2013]. However,
the majority of CMT-associated ARS mutations have been identi-
fied in GARS, and there is conflicting data regarding the presence
or absence of loss-of-function characteristics. The functional con-
sequences of humanGARSmutations have been assessed in enzyme
activity assays, yeast and fly complementation assays, and local-
ization studies in cultured neurons. While many of the mutations
demonstrate a loss-of-function effect in at least one of these assays
[Antonellis et al., 2006; Chihara et al., 2007; Nangle et al., 2007;
Xie et al., 2007; Stum et al., 2011], nine of the thirteen identified
GARS mutations have not been rigorously tested [Wallen and An-
tonellis, 2013]. Indeed, this includes five mutations [p.Ala57Val,
p.Asp146Asn, p.Ser211Phe, p.Pro244Leu, and p.Ile280Phe [James
et al., 2006; Rohkamm et al., 2007; Abe and Hayasaka 2009; Lee
et al., 2012] that have not been evaluated in any assay. Character-
izing the full panel of GARS mutations will be necessary to de-
termine whether a loss-of-function mechanism is a component of
CMT2D and dSMA-V. These data will be critical for a better un-
derstanding of the molecular pathology of ARS mutations and for
developing effective therapies for patients with ARS-related CMT
disease.
Here, we describe genetic, enzyme kinetic, yeast complemen-
tation, and protein localization studies that reveal the functional
consequences of disease-associated GARS mutations. Combined
with previously reported data, our findings support the hypoth-
esis that impaired GARS function plays a central role in CMT2D
and dSMA-V. Additionally, further screening of patients for disease-
associated GARS mutations revealed that a variant previously as-
sociated with neuropathy (p.Ser581Leu) does not segregate with
disease. These findings illustrate the need for careful genetic
and functional evaluation of variants identified in patient pop-
ulations before reporting them as causative factors in human
disease.
Materials and Methods
Computational Assessment of GARSMutations
GARS protein sequences were collected from the NCBI Protein
Database (http://www.ncbi.nlm.nih.gov/protein/) for the indicated
species using the following accession numbers: human (Homo sapi-
ens, accession number AAA57001.1), mouse (Mus musculus, acces-
sion number AAH21747.1), zebrafish (Danio rerio, accession num-
ber XP 692410.4), roundworm (Caenorhabditis elegans, accession
number NP 498093.1), and baker’s yeast (Saccharomyces cerevisiae,
accession number NP 009679.2). Multiple species amino acid se-
quence alignments were then generated using ClustalW2 software
[Larkin et al., 2007].
GARS and GRS1 Expression Constructs
DNAconstructs for aminoacylation, yeast complementation, and
localization studies where generated using Gateway cloning tech-
nology (Invitrogen, Carlsberg, CA). Briefly, the human GARS open
reading framewas amplified fromahuman cDNA sample, and the S.
cerevisiaeGRS1 locuswas amplified fromS. cerevisiae genomicDNA.
Primers were designed with flanking Gateway sequences attB1 (for-
ward) and attB2 (reverse; primer sequences available on request).
Entry clones were generated by recombining PCR-purified ampli-
cons into the pDONR221 vector using BP clonase and the man-
ufacturer’s specifications. After transformation into E. coli, DNA
from individual entry clones was isolated and subjected to DNA se-
quencing analysis to confirm the presence of the appropriate wild-
type gene. For each mutation studied here, mutation-containing
oligonucleotides were generated, and the QuickChange II XL Site-
Directed Mutagenesis Kit (Stratagene, Santa Clara, CA) was used
as per the manufacturer’s instructions. After transformation into
E. coli, DNA from individual clones was purified and sequenced to
confirm the presence of eachmutation and the absence of any cycle-
induced errors. Subsequently, validated entry clones were purified
and recombined into the appropriate Gateway-compatible vector
using LR clonase and the manufacturer’s specifications. The vec-
tors included pET-21a(+) (aminoacylation assays), pEGFP-N2 (for
expressing GARS with a C-terminal EGFP tag), and pRS315 (yeast
complementation assays). DNA from the resulting expression con-
structs was purified and digested with the restriction enzyme BsrGI
(New England Biosystems, Ipswich, MA) to confirm the presence of
the appropriate insert.
Aminoacylation Assays
Wild-type and mutant human GARS proteins (see above) were
expressed in E. coli Rosetta 2 (DE3) pLys cells with a C-terminal in-
frameHis tag and purified with nickel affinity resin according to the
manufacturer’s protocol (Novagen, Rockland, MA). Based on the
wild-type enzyme, the active fraction of humanGARS in our prepa-
rations was20%. The T7 transcript of human tRNAGly/UCU (UCU,
anticodon) was prepared and purified as previously described [Hou
et al., 1993], was heat denatured at 85°C for 3 min, and annealed at
37°C for 20min before use. Steady-state aminoacylation assays were
monitored at 37°C in 50 mMHEPES (pH 7.5), 20 mMKCl, 10 mM
MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 3H-glycine (Perkin
Elmer, Waltham, MA) at a specific activity of 16,500 dpm/pmole.
The reaction was initiated by mixing a GARS enzyme (20–600 nM)
with varying concentrations of tRNA (0.3–20 μM). Aliquots of a
reaction mixture were spotted on filter papers, quenched by 5%
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trichloroacetic acid, washed, dried, and measured for radioactivity
by a liquid scintillation counter (LS6000SC; Beckman Coulter Inc.,
Fullerton, CA). The amount of radioactivity retained on filter pads
was corrected for quenching effects to determine the amount of
synthesis of Gly-tRNAGly. Steady-state kinetics was determined by
fitting the initial rate of aminoacylation as a function of tRNA
concentration to the Michaelis–Menten equation [Schreier and
Schimmel, 1972].
Yeast Complementation Assays
The RJT3/II-1 haploid yeast strain [MATα grs1::HIS3, his3200,
leu21, lys2202, trp63, ura3–52, pTsscII-maint (cen, GRS1,
URA3)] carrying a deleted endogenous GRS1 allele and wild-type
GRS1 on a URA3-bearing pRS316 maintenance vector was previ-
ously reported [Turner et al., 2000; Antonellis et al., 2006]. RJT3/II-
1 was transformed with a LEU2-bearing pRS315 vector containing
wild-type or mutant GRS1 (described above) or pRS315 with no
insert as previously reported [Antonellis et al., 2006]. Each trans-
formation was performed at least four times with at least three in-
dependent plasmid DNA preparations. Four colonies were selected
from each transformation for additional analysis. Each colony was
grown to saturation in –leu -ura selection medium for 48 hr. Next,
10 μL of undiluted and diluted (1:10 and 1:100) samples from
each culture were spotted on plates containing 0.1% 5-fluoroorotic
acid (5-FOA) [Boeke et al., 1987] complete medium, yeast extract–
peptone–glycerol (YPG) plus 0.1% 5-FOA medium, or SD -leu
-ura growth medium (Teknova, Hollister, CA) and incubated at
30°C or 37°C for 72 hr. Yeast cell growth was determined by visual
inspection.
Cell Culture and Protein Localization Studies
The mouse motor neuron, neuroblastoma fusion cell line (MN-
1) was cultured and transfected with constructs to express wild-
type or mutant GARS in-frame with a C-terminal enhanced green
fluorescent protein (EGFP) tag as previously described [Salazar-
Grueso et al., 1991; Antonellis et al., 2006]. After 48 hr, growth
medium was removed, and cells were washed in 1× PBS and then
incubated in 1× PBS/0.4% paraformaldehyde for 10 min at room
temperature. Cells were washed in 1× PBS, costained with 300 nM
DAPI for 5 min, washed again in 1× PBS, and finally coated with
Pro-Long antifade reagent (Invitrogen). Images were obtained with
an IX71 InvertedMicroscopeusing cellSens Standard image software
(Olympus, Center Valley, PA).
Population Screening and Segregation Analysis
The presence of each GARS variant in the general population
was assessed using the Exome Variant Server (snp.gs.washington.
edu/EVS/), the 1000 Genomes Project database (www.
1000genomes.org/), and dbSNP (www.ncbi.nlm.nih.gov/snp). Ad-
ditionally, a search of the GEM.app exome-sequencing database
was performed forGARS variants in patients with CMT disease (ge-
nomics.med.miami.edu). For p.Ser581Leu GARS segregation stud-
ies, oligonucleotide primers were designed to amplify GARS exon
16, which harbors the second and third nucleotides of the serine 581
codon. Patient DNA samples were subjected to PCR amplification
under standard conditions along with a “no DNA” PCR-negative
control reaction. Subsequently, PCRproducts were purified onMini
Spin Columns (Epoch Life Science, Inc., Missouri City, TX), eluted,
and then subjected to Sanger DNA sequencing analysis using the
“forward” and “reverse” amplification primers in separate reactions
(University of Michigan DNA Sequencing Core). The appropri-
ate review boards of each participating institution approved these
studies.
Results
Localization and Conservation of Human GARSMutations
GARS mutations found in patients with CMT disease are dis-
tributed throughout the primary structure of the protein. Notably,
the mutations affect conserved residues, which are often conserved
between human and yeast, suggesting a critical role in protein func-
tion [Antonellis et al., 2003]. To determine whether newly reported
GARS mutations demonstrate a similar level of conservation, we
mapped the residues onto the human protein and generated an
alignment with evolutionarily diverse organisms (Fig. 1A and B).
Mutations were evenly distributed throughout the major functional
domains of the protein [Xie et al., 2007] (Fig. 1A): (1) p.Ala57Val
affects a residue in the disordered WHEP–TRS domain (residues
13–63; pfam00458 in the NCBI Conserved Domain Database),
which is putatively involved in tRNA binding and interacting with
other ARSs in enzyme complexes [Ray et al., 2011], but that is
not critical for GARS function [Xie et al., 2007]; (2) p.Asp146Asn,
p.Pro244Leu, and p.Ile280Phe affect amino acids in the catalytic
core (residues 92–168, 241–305, and 350–418; pfam 00587) respon-
sible for ligation of glycine to tRNA; (3) p.Ser211Phe, p.His418Arg,
and p.Asp500Asn affect amino acids within insertion domains of
unknown function; and (4) p.Ser581Leu and p.Gly598Ala reside in
the anticodon-binding domain (residues 557–655; pfam03129) that
binds to glycine-specific tRNAs.
The evolutionary conservation of mutated GARS residues varies
greatly (Fig. 1B). Asp146, Pro244, Ile280, and His418 are identical
between human and yeast, whereas Ser211 and Gly598 are con-
served, but to a lesser degree (e.g., between human and worm). In
contrast, Ala57 is conserved among mammals and worm, but not
zebrafish, and Asp500 and Ser581 are conserved only among verte-
brates. Thus, Asp146, Ser211, Pro244, Ile280, His418, and Gly598
are predicted to be critical for enzyme function, whereas Ala57,
Asp500, and Ser581 are less likely to be essential for GARS activity.
The Majority of GARSMutations Reduce Aminoacylation
Activity
The primary function of ARS enzymes is to charge tRNA
molecules with cognate amino acids [Delarue, 1995] in a two-step
aminoacylation reaction: (1) binding and activation of the amino
acid with ATP and (2) conjugation of the activated amino acid to
the 3′ end of the appropriate tRNA [Antonellis and Green, 2008].
The aminoacylation assay evaluates the combined reactions of both
steps and has been used to establish whether CMT-associated ARS
mutations disrupt this critical canonical function [Nangle et al.,
2007; McLaughlin et al., 2010; Froelich and First, 2011; McLaughlin
et al., 2011]. Here, we assessed previously untested GARS variants
(p.Ala57Val, p.Asp146Asn, p.Ser211Phe, p.Pro244Leu, p.Ile280Phe,
p.His418Arg, andp.Gly598Ala) for the ability to chargehumancyto-
plasmic tRNAGly with tritium-labeled glycine. For comparison pur-
poses, we included twoGARSmutations previously shown to impair
enzymekinetics: p.Gly240Argandp.Gly526Arg [Nangle et al., 2007].
With regard to the untested variants, p.Asp146Asn, p.Ser211Phe,
p.Pro244Leu, p.Ile280Phe, p.His418Arg, and p.Gly598Ala GARS
demonstrate less than 10% aminoacylation activity compared to
wild-type GARS (Table 1). In contrast, p.Ala57Val displayed the
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Figure 1. Localization and conservation ofGARS variants.A: Mutations are depicted on a cartoon of the known functional and structural domains
of GARS in blue (WHEP–TRS domain), red (catalytic domain), yellow (insertion domains), and green (anticodon-binding domain). The amino acid
positions for each domain are indicated below the cartoon. B: GARS protein sequence alignments from multiple, evolutionarily diverse species are
depicted. The amino acid change is listed at the top of each protein fragment. The affected amino acid is in bold, red text. [Figure in color in online
version].
Table 1. Aminoacylation Kinetics of GARS Protein Variants
Variant Km (μM) kcat (s-1) kcat/Km (μM-1/sec) Relative to WT
Wild type 1.03 ± 0.03 0.14 ± 0.02 0.14 ± 0.02 1
p.Ala57Val 0.92 ± 0.22 0.07 ± 0.01 0.07 ± 0.02 1/2
p.Asp146Asn 0.6 ± 0.1 0.006 ± 0.002 0.01 ± 0.01 1/14
p.Ser211Phe - - (3.2 ± 1.5) × 10-5 1/4,400
p.Gly240Arg 3.2 ± 0.6 (4.2 ± 0.3) × 10-3 (1.3 ± 0.4) × 10-3 1/110
p.Pro244Leu - - Undetectable Undetectable
p.Ile280Phe - - (7.9 ± 2.0) × 10-5 1/1,700
p.His418Arg 0.004 ± 0.001 (3.9 ± 0.1) × 10-5 0.01 ± 0.01 1/16
p.Gly526Arg 7.1 ± 1.3 (2.3 ± 0.4) × 10-5 (3.2 ± 2.0) × 10-6 1/ 44,000
p.Gly598Ala 1.4 ± 0.3 (1.1 ± 0.1) × 10-3 (7.9 ± 3.0) × 10-4 1/180
Amino-acid coordinates correspond to GenBank accession number AAA57001.1.
± Indicates standard deviations.
- Indicates that kcat and km are not directly measured; the value for kcat/Km (where applicable) was measured under an approximate condition where the substrate concentration
is below an estimated Km.
“Undetectable" indicates that values are below the limits of detection.
ability to charge tRNAGly molecules with a much higher efficiency
than other mutant proteins, albeit with a 50% reduction relative to
wild-type GARS.
The Majority of Testable GARSMutations Dramatically
Reduce Yeast Cell Viability
Yeast complementation assays have been performed to determine
the functional consequences of CMT-associated ARS mutations in
the context of a living cell [Antonellis et al., 2006; Jordanova et al.,
2006; McLaughlin et al., 2010; Stum et al., 2011; McLaughlin et al.,
2011; Vester et al., 2012; Gonzalez et al., 2013]. Here, mutations
are modeled in the S. cerevisiae GARS ortholog GRS1, and cellular
growth is used as a proxy for enzyme function; this model employs
a haploid yeast strain with the endogenous GRS1 locus deleted
and viability maintained via expression of wild-type GRS1 on a
URA3-bearing maintenance vector [Turner et al., 2000; Antonel-
lis et al., 2006; Stum et al., 2011] (Fig. 2A). Based upon ClustalW
alignments (Fig. 1B), we identified the orthologous GRS1 amino
acid of each previously untested GARS mutation and performed
site-directed mutagenesis to model the human mutations in yeast.
We were able to confidently model p.Asp146Asn, p.Pro244Leu,
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Figure 2. Characterization of yeast expressing wild-type and mu-
tantGRS1. Cartoon illustrates yeast complementation strategy (A). Each
yeast strain was transformed with a LEU2-bearing pRS315 vector con-
taining wild-type GRS1 (Wt), the indicated mutant form of GRS1 (Mut),
or no insert (“Empty”). Cultures for each strain (labeled along the top for
each panel in B–D) were grown for 2 days in liquid media and spotted
on selective solid growth medium directly or after dilution as indicated.
Strains were plated on medium containing 5-FOA to determine whether
the GRS1 alleles complement loss of the GRS1 gene at 30°C (B) and
37°C (C). D: Strains were plated on solid medium containing 5-FOA and
glycerol (YPG) to assess for an effect on mitochondrial function.
and p.Ile280Phe GARS in GRS1 based on homology; p.Ala57Val,
p.Ser211Phe, p.Asp500Asn, and p.Ser581Leu are not conserved be-
tween human and yeast and thus could not be modeled in this as-
say. Based on protein alignments, p.Asp146Asn, p.Pro244Leu, and
p.Ile280Phe GARS (GenBank accession number AAA57001.1) cor-
respond to p.Asp96Asn, p.Pro227Leu, and p.Ile255Phe GRS1 (Gen-
Bank accession number NP 009679.2), respectively. GRS1 muta-
tions are referred to in Figure 2 based on the human mutation they
model. Yeast cells were transformed with the experimental alleles
on a LEU2-harboring vector and plated on solid growth medium
containing 0.1% 5-FOA (Fig. 2A). 5-FOA is toxic to yeast cells ex-
pressingURA3 and thus selects for cells that have spontaneously lost
the maintenance vector [Boeke et al., 1987]. Only yeast cells con-
taining a functional GRS1 allele on the LEU2-bearing experimental
plasmid are able to complement the deleted endogenous GRS1 al-
lele and survive on 5-FOA plates. Our wild-type GRS1 expression
construct allowed robust yeast cell growth and our experimental
vector without a GRS1 gene (“Empty” in Fig. 2B) was unable to
complement the null allele in yeast cells (Fig. 2B). These results are
consistent with the construction of a functionalGRS1 experimental
system and with GRS1 being an essential gene, respectively [Turner
et al., 2000; Antonellis et al., 2006]. With regard to the modeled
mutations, p.Ile280Phe GRS1 was able to maintain yeast viability
(Fig. 2B) in a comparable manner to wild-type GRS1. In contrast,
p.Asp146Asn and p.Pro244Leu GRS1 resulted in a severe reduction
of yeast cell growth compared to wild-type GRS1 (Fig. 2B). We also
evaluated yeast cells incubated at 37°C to assess for temperature-
sensitive effects of the studied mutations. These analyses did not
reveal any further depletion of growth associated with the modeled
mutations compared to wild-type GRS1 (Fig. 2C). Finally, since
GARS is a bifunctional ARS enzyme responsible for charging tRNA
in both the cytoplasm and mitochondria [Antonellis and Green,
2008], yeast cells were grown on medium containing glycerol and
5-FOA at 30°C to require yeast to rely solely on mitochondrial
respiration, which allows the detection of impaired mitochondrial
function. Similar to the studies at 37°C, the relative pattern of via-
bility remained consistent when comparing mutant and wild-type
GRS1 and therefore did not reveal any further mutation-dependent
depletion in yeast cell growth (Fig. 2D). Thus, two of the three
human GARS mutations modeled in GRS1 dramatically decrease
cell viability in vivo when expressed in isolation, consistent with a
loss-of-function effect.
The Majority of GARSMutations Reduce Punctate
Localization in Cultured Neurons
The wild-type GARS protein localizes to “puncta” within axons
in the human peripheral nerve where it likely functions in local pro-
tein translation [Antonellis et al., 2006]. Certain GARS mutations
impair the punctate localization in cultured neurons, suggesting
that reduced localization to axons is a component of CMT2D and
dSMA-V disease pathogenesis [Antonellis et al., 2006]. However,
not all GARS mutations have been tested for an effect on puncta
formation in neuronal cells. We therefore expressed wild-type and
eight untestedmutant GARS–EGFP fusion proteins in amousemo-
tor neuron, neuroblastoma fusion cell line (MN-1 cells) [Salazar-
Grueso et al., 1991; Antonellis et al., 2006]. Fluorescencemicroscopy
revealed that wild-type, p.Ala57Val, p.Asp146Asn, p.Asp500Asn,
and p.Ser581Leu GARS-EGFP all demonstrated a punctate local-
ization pattern in MN-1 cells (Fig. 3A–C, G, and H). In contrast,
p.Ser211Phe, p.Pro244Leu, p.Ile280Phe, and p.Gly598Ala GARS–
EGFPproteins did not associatewith puncta inMN-1 cells (Fig. 3D–
F, and I). Importantly, for the mutant GARS–EGFP proteins that
did form puncta, these structures were also observed in MN-1 neu-
rite projections, consistent with previous observations of wild-type
GARS localization (data not shown) [Antonellis et al., 2006; Fallini
et al., 2011].
p.Ser581Leu GARS Does Not Segregate with Disease in
Newly Discovered Pedigrees
The p.Ala57Val variant was identified in a single individual with
weakness and muscle wasting in the upper extremities [Rohkamm
et al., 2007], and p.Ser581Leu was identified in a single proband
with an extensive family history of lower limb predominant axonal
CMT disease [James et al., 2006]. No further segregation analy-
ses were performed on either mutation. Furthermore, ethnically
matched control populations were not screened for the absence of
p.Ala57Val or p.Ser581Leu. Therefore, we searched genome variant
databases for the occurrence of these two mutations. p.Ala57Val
and p.Ser581Leu were both identified by the NHLBI GO Exome Se-
quencing Project at a low frequency of 1/11,842 (rs370531212:C>T)
and 2/11940 (rs201358272:C>T), respectively. The other 11 GARS
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Figure 3. Expression of wild-type and mutant GARS in mouse motor neuron-derived cells. MN-1 cells expressing EGFP-tagged wild-type (A),
p.Ala57Val (B), p.Asp146Asn (C), p.Ser211Phe (D), p.Pro244Leu (E), p.Ile280Phe (F), p.Asp500Asn (G), p.Ser581Leu (H), or p.Gly598Ala GARS (I) were
evaluated for the presence or absence of puncta by fluorescence microscopy. [Figure in color in online version]
mutations associated with disease have not been reported in control
or general populations.
Our on-going mutation analyses revealed p.Ser581Leu GARS in
two unrelated probands with dominant axonal CMT disease. To
determine whether this mutation is associated with disease in the
two respective families, we performed segregation studies. DNA
sequence analysis of additional affected individuals revealed that
p.Ser581Leu GARS does not segregate with disease in either family
(Fig. 4A and B). Specifically, clinically affected individuals in these
two families do not carry p.Ser581Leu GARS. Combined with the
identification of this variant in the general population, these data
indicate that p.Ser581LeuGARS should not be considered a disease-
causing mutation.
Discussion
ARSs are essential enzymes that charge tRNA molecules with
cognate amino acids [Delarue, 1995]. Interestingly, genes encod-
ing ARSs have been implicated in a phenotypically diverse panel
of dominant and recessive diseases [Wallen and Antonellis, 2013].
While the majority of disease-associated alleles demonstrate a pri-
mary loss of function, only four of the 13 reported GARS muta-
tions have been rigorously tested. In this study, we evaluated nine
GARS mutations, and our results indicate that impaired function,
either by reduced enzyme function or altered cellular localization, is
an important component of CMT disease pathogenesis. We deter-
mined that p.Asp146Asn, p.Ser211Phe, p.Pro244Leu, p.Ile280Phe,
p.His418Arg, and p.Gly598Ala GARS encode a protein product
with a severe defect in tRNA charging. Additionally, p.Ser211Phe,
p.Pro244Leu, p.Ile280Phe, and p.Gly598Ala GARS proteins fail to
form puncta characteristic of wild-type GARS [Antonellis et al.,
2006; Fallini et al., 2011]. Finally, our genetic analyses rule out
p.Ser581Leu GARS as a pathogenic mutation. Combined with pre-
vious reports, the data presentedhere reveal that 10 of the 12 disease-
associated GARS mutations identified to date demonstrate loss-of-
function characteristics [Antonellis et al., 2006; Chihara et al., 2007;
Nangle et al., 2007; Xie et al., 2007; Stum et al., 2011]. This study fur-
thers our understanding of the allelic spectrum of GARS-associated
CMT disease and suggests that impaired GARS function is an im-
portant component of the axonal peripheral neuropathy.
Aminoacylation and yeast growth assays are established systems
for testing the function of ARS enzymes in vitro and in vivo, re-
spectively. Importantly, all GARS mutations that fail to comple-
ment yeast cell growth also have a severe reduction in aminoacy-
lation activity. However, certain mutations, such as p.Ile280Phe,
show reduced aminoacylation activity in vitro but complement
yeast cell growth in a manner similar to the wild-type enzyme.
One possible explanation for this discrepancy is that bacterially
produced proteins may lack post-translational modifications im-
portant for enzyme function in human cells or for proper activ-
ity in specific cellular contexts. Additionally, other cellular compo-
nents may stabilize the mutant protein product in the yeast sys-
tem, allowing for improved function and viability. The yeast assay
could not be used to evaluate all GARS mutations due to a lack of
conservation with human residues. Alternative assays (see below)
should be explored to determine the in vivo consequences of such
mutations.
While yeast offers insight into the functional consequences of
GARS mutations in vivo, it does not reveal how GARS mutations
affect axons. The function of GARS and other ARS enzymes in ax-
ons remains unclear; however, there is strong evidence that they
provide tRNA charging for local protein translation [Ingoglia et al.,
1983; Giuditta et al., 2002]. Interestingly, wild-type endogenous
GARS forms discrete puncta in peripheral neurons and axons from
healthy human subjects [Antonellis et al., 2006]. Data collected to
date show that seven of the 12 disease-associated GARS mutations
give rise to proteins that are unable to localize to puncta in cul-
tured neurons (Table 2). Another study showed that mutant GARS
proteins mislocalize in neurite projections [Nangle et al., 2007] but
did not reveal discrete puncta, which is likely due to differential
placement of the epitope tag. The loss of a punctate localization
pattern observed for certain GARS mutant proteins may be due to
altered protein structure and/or reduced binding to specific protein
partners or RNAmolecules required for puncta formation. It will be
critical to identify proteins and/or RNAs that GARS interacts with
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Figure 4. p.Ser581Leu GARS does not segregate with CMT disease.
DNA samples from affected individuals from two presumably unrelated
familieswith autosomal-dominant, axonal CMTdiseaseweregenotyped
for p.Ser581Leu GARS. Female patients are indicated with circles and
male patients are indicated with squares. Filled symbols represent af-
fected individuals with a diagnosis of dominant axonal CMT disease,
and empty symbols indicate unaffected individuals. Where applicable,
an individual’s genotype is indicted with + (for the wild-type allele) or
p.Ser581Leu (for the variant allele). A: Samples from individuals in Fam-
ily 1 were anonymized resulting in loss of the pedigree structure for
this family; however, individuals 1178-1 and 1178-2 are directly related,
both affected, and reside in a pedigree originally described as dominant
axonal CMT disease. Representative chromatographs from sequenc-
ing analysis of genomic DNA from affected individuals are shown. The
sequence includes the AG splice-site acceptor at the 3′ end of intron
15 followed by the first 12 nucleotides of exon 16 (intron/exon junction
marked by dashed line). The p.Ser581 codon (TCG) is encoded by the
last nucleotide of exon 15 (T; not shown) and the first two nucleotides
(CG) of exon 16. Individual 1,178-1 is heterozygous for a C > T mutation
(red arrow) in the first base of exon 16 resulting in the p.Ser581Leu allele.
1,178-2 is homozygous for the wild-type genotype at this nucleotide (C).
B: The pedigree for Family 2 illustrates the affected status of each family
member and the p.Ser581Leu genotypes of two affected individuals with
dominant axonal CMT disease. [Figure in color in online version]
in these structures to further understand puncta function and how
disruption of these structures may lead to CMT disease.
Although impaired function is associated with GARS-mediated
CMT disease, three disease-associated mutations have not demon-
strated impaired function in any of the assays used in this
study: p.Ala57Val, p.Glu71Gly, and p.Asp500Asn (Table 2). The
p.Glu71Gly GARSmutation segregates with disease in a large pedi-
greewith upper limb predominant axonal neuropathy characteristic
of CMT2D [Antonellis et al., 2003]. Analysis of human p.Glu71Gly
GARS in a fly model revealed that it cannot complement the loss
of gars in neurons, and the authors conclude that p.Glu71Gly rep-
resents a loss-of-function allele [Chihara et al., 2007]. Similar to
p.Glu71Gly, p.Asp500Asn GARS segregates with disease in a large
pedigree with dominantly inherited, upper limb predominate ax-
onal neuropathy [Del Bo et al., 2006], providing strong genetic and
phenotypic evidence supporting a role in CMT2D disease patho-
genesis. In contrast, p.Ala57Val has weak genetic evidence for a role
in CMT disease. First, this variant was identified in a single individ-
ual with upper limb predominant CMT disease and no additional
family members were available for segregation studies [Rohkamm
et al., 2007]. Second, ethnically matched controls were not tested
to determine the presence of this allele in appropriate populations.
Finally, p.Ala57Val was identified by the NHLBI GO Exome Se-
quencing Project (rs370531212:C>T) at a low frequency; however,
since individuals in the NHLBI study were not subjected to neu-
rological examination and since CMT is often a late-onset disease,
inclusion in this database does not exclude p.Ala57Val from having
a causative role in CMT disease. Evaluation of p.Asp500Asn and
p.Ala57Val in the fly model will be important to determine whether
these variants have impaired function that cannot be detected by
other assays.
To date, loss-of-function mutations at five ARS loci have been
implicated in dominantly inherited CMT disease [Antonellis et al.,
2003; Jordanova et al., 2006; Latour et al., 2010; Vester et al., 2012;
Gonzalez et al., 2013]. Thus, mechanisms of impaired function in
dominant disease should be carefully evaluated, including haploin-
sufficiency, a dominant-negative effect, and a toxic gain of function.
First, while mice heterozygous for loss-of-function missense Gars
mutations (C201R and P234KY) demonstrate a dominant axonal
neuropathy [Seburn et al., 2006; Achilli et al., 2009; Motley et al.,
2011], mice heterozygous for a Gars null (gene-trap) allele have a
wild-typephenotype [Seburnet al., 2006]. In addition,GARSnull al-
leles have not been identified in patients with CMT2D and dSMA-V.
Combined, these findings argue against haploinsufficiency. Second,
transgenic overexpression of wild-type human GARS in the two
mouse models restored viability but did not rescue the neuropa-
thy phenotype [Motley et al., 2011], arguing against a dominant-
negative effect. However, overexpression of human GARS was un-
able to rescue the lethality associated with homozygosity for the
Gars gene trap allele, indicating that the cDNA transgene may not
function in all tissues and during all developmental periods [Mot-
ley et al., 2011]. Thus, it will be important to assess the activity of
wild-type:mutant GARS dimers and the effect of wild-type GARS
overexpression in the context of mutations identified in human pa-
tients before excluding a dominant-negative mechanism [Wallen
and Antonellis, 2013]. Finally, impaired GARS function may be
a prerequisite for a toxic gain-of-function effect. While mutant
protein aggregates have not been reported [Antonellis et al., 2006;
Seburn et al., 2006; Nangle et al., 2007; Achilli et al., 2009; Motley
et al., 2011; Stum et al., 2011], conformational changes of human
mutant GARS proteins have been observed [He et al., 2011]. These
proteins should be assessed for mutant-specific binding to neuronal
RNAs and/or proteins. If these experiments are informative, then
therapies should be designed to reduce the expression of mutant
GARS alleles in patients with CMT2D [Motley et al., 2011]. Impor-
tantly, the three pathogenic mechanisms outlined here are not mu-
tually exclusive; mutation-specific utilization of haploinsufficiency,
dominant-negative, and/or toxic gain-of-function effects may ex-
plain the observed clinical spectrum of GARS-associated peripheral
neuropathy.
The development of rapid, affordable technologies has allowed
the use of DNA sequencing for research and diagnostic purposes.
Importantly, once a gene is implicated in disease, patients with
a similar phenotype can be rapidly screened for variants at that
locus. However, rare variants identified in individual patients or
small pedigrees are difficult to implicate in disease phenotypes due
to the absence of strong genetic evidence [MacArthur et al., 2014].
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Table 2. Summary of Functional Studies on GARS Variants
Variant Enzyme activity Yeast viability Puncta formation References
Wild type Normal Viable Yes Antonellis et al., 2006; and this study
p.Ala57Val Normala NA Yes This study
p.Glu71Gly Normal Viable Yes Antonellis et al., 2006; Nangle et al. 2006
p.Leu129Pro Reduced Reduced No Antonellis et al., 2006; Nangle et al., 2006
p.Asp146Asn Reduced Reduced Yes This study
p.Ser211Phe Reduced NA No This study
p.Gly240Arg Reduced Viable No Antonellis et al., 2006; Nangle et al., 2006
p.Pro244Leu Reduced Lethal No This study
p.Ile280Phe Reduced Viable No This study
p.His418Arg Reduced Lethal No Antonellis et al., 2006; Nangle et al., 2006; and this study
p.Asp500Asn Normal NA Yes Nangle et al., 2006; and this study
p.Gly526Arg Reduced Lethal Yes Antonellis et al., 2006; Nangle et al., 2006; Xie et al., 2007
p.Ser581Leu Normal NA Yes Nangle et al., 2006; Cader et al., 2007; and this study
p.Gly598Ala Reduced Viable No Stum et al., 2011; and this study
Amino acid coordinates correspond to GenBank accession number AAA57001.1.
Bold text indicates a result consistent with a loss-of-function effect.
aThis variant was associated with50% activity compared with wild-type GARS and we considered a >90% reduction in activity as dramatically “reduced.”
NA, not applicable; mutation could not be modeled in yeast ortholog.
Here, we demonstrate that p.Ser581Leu GARS, a rare variant pre-
viously identified in patients with CMT disease, does not segre-
gate with neuropathy in two newly identified families with domi-
nant axonal CMT disease. This variant was originally identified in
individuals with lower limb predominant CMTdisease [James et al.,
2006], which is uncharacteristic ofGARS-associated CMT2D. Inter-
estingly, p.Ser581Leu has normal aminoacylation activity [Nangle
et al., 2007] and localization in neurons (Fig. 3). Thus, our data
indicate that p.Ser581Leu is not a primary disease-causing muta-
tion and should be removed from further studies to determine the
pathogenic mechanism of GARSmutations.
Conclusion
Our data indicate that impaired function is a common charac-
teristic of CMT-associated GARS mutations and that this may be
a necessary first step for disease pathogenesis. However, additional
research is needed to implicate or refute a causative link between
impaired tRNA charging and CMT2D disease. Importantly, deter-
mining the precise mechanism of mutant GARS toxicity in axons
will be essential for designing effective therapies for patients with
CMT2D.
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